<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00827450</url>
  </required_header>
  <id_info>
    <org_study_id>COLIBRI</org_study_id>
    <nct_id>NCT00827450</nct_id>
  </id_info>
  <brief_title>Effects of Coffee on Hepatic Steatosis Induced by a High Fructose Diet</brief_title>
  <acronym>COLIBRI</acronym>
  <official_title>Effects of Coffees With Various Compositions of Antioxidants on Hepatic Steatosis Induced by a High Fructose, Hypercaloric Diet</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Lausanne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nestl√© Research Center, Vers-chez-les-blanc, Switzerland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Lausanne</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess

        -  whether coffee consumption protects against fructose-induced hepatic steatosis in
           healthy humans

        -  whether the protective effect of coffee is dependent on it's antioxidant composition
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epidemiological studies suggest that coffee consumption improves glucose homeostasis in
      insulin resistant subjects. An increase in intrahepatic lipids (hepatic steatosis) is highly
      prevalent in patients with the metabolic syndrome and may be used as a marker of altered
      hepatic lipid metabolism. Such an increased hepatic lipids content can be experimentally
      produced in healthy humans by a 6-day high fructose diet.

      The purpose of this study is to evaluate whether coffee prevents hepatic lipid deposition in
      healthy male subjects fed a fructose-rich hypercaloric diet. Both caffeine and antioxidants
      (yet unspecified) may be involved.. To sort out the role of caffeine and antioxidants, we
      will test 3 different soluble coffee, ie fully torrefied decaffeinated coffee , partially
      torrefied decaffeinated coffee, and partially torrefied caffeinated coffee.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>intra-hepatocellular lipid (IHCL) concentration</measure>
    <time_frame>will be measured after 6 days on a hypercaloric, high fructose (4g/kg body weight/day) diet +/- treatement</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>fasting plasma triglycerides</measure>
    <time_frame>will be measured after 6 days on a hypercaloric, high fructose (4g/kg body weight/day) diet +/- treatement</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting net lipid oxidation</measure>
    <time_frame>will be measured after 6 days on a hypercaloric, high fructose (4g/kg body weight/day) diet +/- treatement</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting net carbohydrate oxidation</measure>
    <time_frame>will be measured after 6 days on a hypercaloric, high fructose (4g/kg body weight/day) diet +/- treatement</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>whole body ketone bodies turnover and oxidation (13C 3-hydroxybutyrate)</measure>
    <time_frame>will be measured after 6 days on a hypercaloric, high fructose (4g/kg body weight/day) diet +/- treatement</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>whole body glucose turnover (6,6 2H2 glucose)</measure>
    <time_frame>will be measured after 6 days on a hypercaloric, high fructose (4g/kg body weight/day) diet +/- treatement</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>whole body glycerol turnover (2H5 glycerol)</measure>
    <time_frame>will be measured after 6 days on a hypercaloric, high fructose (4g/kg body weight/day) diet +/- treatement</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Hepatic Steatosis</condition>
  <arm_group>
    <arm_group_label>Ctl</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>control isocaloric diet; no coffee</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HF</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Hypercaloric. high fructose diet; no coffee</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypercaloric, high fructose diet; caffeine-free, torrefied coffee</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypercaloric, high fructose diet; caffeine-free, partially torrefied coffee</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hypercaloric, high fructose diet; caffeinated, partially torrefied coffee</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ctl</intervention_name>
    <description>Control, isocaloric diet; no coffee</description>
    <arm_group_label>Ctl</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>High fructose diet; no coffee</intervention_name>
    <description>Hypercaloric, high fructose diet; no coffee</description>
    <arm_group_label>HF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>fully torrefied, caffeine-free coffee</intervention_name>
    <description>Hypercaloric, high fructose diet + coffee</description>
    <arm_group_label>C1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>partially torrefied, caffeine-free coffee</intervention_name>
    <description>Hypercaloric, high fructose diet + coffee</description>
    <arm_group_label>C2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Partially torrefied, caffeinated coffee</intervention_name>
    <description>Hypercaloric, high fructose diet + coffee</description>
    <arm_group_label>C3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI between 19 and 15 kg/m2

          -  less than 30 min physical activity /day

          -  habitual coffee consumption less than three cupy /day

          -  consumption of caffeine-containing sodas less than 2 servings/day

          -  non-smoker

        Exclusion Criteria:

          -  consumption of alcohol more than 40g/day

          -  presence of metallic foreign bodies

          -  history of eye surgery

          -  family history of diabetes mellitus

          -  history of food intolerance

          -  vegetarians
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luc Tappy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Physiology, University of Lausanne, Switzerland</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre d'investigations cliniques &quot;cardiomet&quot;/ CHUV</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2009</study_first_submitted>
  <study_first_submitted_qc>January 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2009</study_first_posted>
  <last_update_submitted>February 23, 2012</last_update_submitted>
  <last_update_submitted_qc>February 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Lausanne</investigator_affiliation>
    <investigator_full_name>Luc Tappy, MD</investigator_full_name>
    <investigator_title>professor of physiology</investigator_title>
  </responsible_party>
  <keyword>hepatic steatosis</keyword>
  <keyword>coffee</keyword>
  <keyword>fructose</keyword>
  <keyword>lipids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Caffeine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

